PillsCard
Brewing the data…
PillsCard
Brewing the data…
Deze informatie is alleen voor educatieve doeleinden.
Beschrijving, Dosering, Bijwerkingen, Contra-indicaties. Data from EMA, URPL, openFDA and other regulatory sources.
| Empagliflozin | Dapagliflozin | |
|---|---|---|
| Werkzame stoffen | EMPAGLIFLOZIN | DAPAGLIFLOZIN |
| ATC-code | A10BK03 | A10BK01 |
| Vorm | TABLET | TABLET |
| Dosering | 10MG | 10MG |
| Toedieningsweg | ORAL | ORAL |
| Fabrikant | BOEHRINGER INGELHEIM PHARMACEUTICALS INC | AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD |
Empagliflozin (INN: EMPAGLIFLOZIN, ATC A10BK03) and Dapagliflozin (INN: DAPAGLIFLOZIN, ATC A10BK01) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Deze informatie is alleen voor educatieve doeleinden.